<DOC>
	<DOCNO>NCT02249429</DOCNO>
	<brief_summary>The main goal study determine Maximum Tolerated Dose ( MTD ) Recommended Phase II Dose ( RP2D ) well preliminary antitumor activity PQR309 administer orally , daily capsule continously patient relapse refractory lymphoma .</brief_summary>
	<brief_title>Open-Label , Non Randomized Phase 2 Study With Safety Run-In</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<criteria>1 . Histologically confirm diagnosis* relapse refractory lymphoma , receive least two prior line therapy include immunochemotherapy . Patients relapse Chronic Lymphoid Leukemia ( CLL ) eligible receive one prior line approve standard therapy . * archival biopsy may use obtain year prior enrollment ; rebiopsy strongly recommend last biopsy obtain year ago . 2 . Only patient Phase 2 part : At least one measurable nodal extranodal lesion define follow : Clearly measurable ( i.e . welldefined boundary ) least two perpendicular dimension image scan &gt; 1.5 cm long transverse diameter . 3 . Age ≥ 18 year 4 . Eastern Cooperative Oncology Group ( ECOG ) Performance Score 01 ( See Appendix 2 ) . 5 . Adequate organ system function define : 1 . Absolute neutrophil count ( ANC ) ≥1.0x109/l 2 . Platelets ≥ 75x109/l 3 . Haemoglobin ≥ 85g/L 4 . Adequate hepatic function , define Total bilirubin ≤ 1.5 time upper limit normal ( ULN ) Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤ 2.5 time ULN ( ALT/AST ≤ 5 time ULN patient liver involvement ) 5 . Adequate renal function , define serum creatinine ≤ 1.5 time ULN 6 . Fasting glucose &lt; 7.0 mmol/L ; Glycated haemoglobin ( HbA1c ) &lt; 6.4 % 6 . Ability willingness swallow retain oral medication . 7 . Willingness ability comply trial procedure 8 . Female male patient reproductive potential must agree use effective contraception screen 90 day discontinuation PQR309 9 . Signed informed consent Any follow condition precludes enrollment patient : 1 . Immunosuppression due : Allogeneic hematopoietic stem cell transplant ( HSCT ) Any immunesuppressive therapy within 4 week prior trial treatment start Known HIV infection 2 . Autologous stem cell transplant within 3 month prior trial treatment start . 3 . Concomitant anticancer therapy ( e.g . chemotherapy , radiotherapy , hormonal therapy , immunotherapy , biological response modifier , signal transduction inhibitor ) . 4 . Concomitant treatment medicinal product increase pH ( reduce acidity ) upper gastrointestinal tract , include , limited , protonpump inhibitor ( e.g . omeprazole ) , H2antagonists ( e.g . ranitidine ) antacid . Patients may enrol study washout period sufficient terminate effect . 5 . Use investigational drug within 21 day prior trial treatment start . 6 . Patients experience National Cancer Institute ( NCI ) Common Terminology Criteria For Adverse Events ( CTCAE ) ≥ Grade 3 PI3K/mTOR inhibitor 7 . Any major surgery , chemotherapy immunotherapy within 21 day prior trial treatment start . 8 . Symptomatic progressing Central nervous system ( CNS ) involvement . Exception : Patients meningeal involvement include upon discussion sponsor investigator . 9 . Persisting toxicity NCI CTCAE ≥2 relate prior anticancer therapy 10 . Presence gastrointestinal disease condition could interfere significantly absorption study drug . 11 . Severe/unstable angina , myocardial infarction coronary artery bypass within last 3 year prior trial treatment start , symptomatic congestive heart failure New York Heart Association ( NYHA ) Class 3 4 , hypertension BP &gt; 150/100mmHg 12 . A serious active infection time treatment , another serious underlie medical condition could impair ability patient receive treatment . 13 . Lack appropriate contraceptive measure ( male female ) 14 . Pregnant lactate woman 15 . Known HIV infection 16 . Significant medical condition could jeopardize compliance protocol . 17 . Uncontrolled diabetes mellitus ; patient control diabetes may enrol ( see fast glucose HbA1c level inclusion criterion ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>